Eduovisual
Biostatistics & Population Health
Herd immunity and vaccine policy
— Measles R₀ ≈ 12–18 → HIT ~92–95%
— Pertussis R₀ ≈ 12–17 → HIT ~92–94%
— Mumps/rubella R₀ ≈ 4–7 → HIT ~75–86%
— Polio R₀ ≈ 5–7 → HIT ~80–86%
— Smallpox R₀ ≈ 5–7 → HIT ~80–85%
— Seasonal influenza R₀ ≈ 1.3–1.8 → HIT ~25–45% (but waning immunity and antigenic drift undermine this)
— A cluster of vaccine-preventable disease (VPD) cases in a community, school, daycare, religious enclave, or healthcare facility
— Disease appearing in age groups previously controlled (e.g., measles in unvaccinated toddlers, pertussis in infants <2 months)
— Imported index case followed by secondary spread among under-vaccinated contacts
— Outbreaks in pockets with documented low MMR or DTaP uptake (philosophical/religious exemptions, vaccine hesitancy)
— Infants below the recommended vaccination age
— Immunocompromised (chemotherapy, HSCT, solid organ transplant, advanced HIV, biologics)
— Pregnant patients (for live vaccines)
— Primary vaccine failures (~2–5% even with proper dosing)
— Patients with contraindications (severe egg allergy for some, anaphylaxis to prior dose)
Board pearl: If you see "measles outbreak in a community with 85% MMR coverage" — the HIT (~95%) is not met; expect ongoing transmission until coverage rises or the susceptible pool is exhausted.
— Unvaccinated traveler returns from country with endemic measles/polio → index case at school/clinic
— Infant <12 months (too young for MMR) develops measles after exposure at a pediatric waiting room
— Healthcare worker without documented immunity transmits varicella or measles to inpatients
— Pertussis cluster in a high school with waning Tdap immunity (adolescents, ~5–10 yr post-Tdap)
— Mumps outbreak on a college campus despite 2-dose MMR coverage (waning immunity → 3rd dose recommended during outbreaks)
— Exact vaccine record with dates, lot numbers if available (do not accept "fully vaccinated" — document)
— Country of birth and immigration status (different schedules; verify with serology if records unavailable)
— Religious, philosophical, or medical exemption status
— Recent international travel of patient or close contacts
— Daycare, school, college dorm, military barracks, cruise ship, congregate housing exposure
— Immunocompromising conditions or therapies in patient or household members
— Pregnancy status (affects live vaccine eligibility and timing)
— Identify the specific concern (autism myth, ingredients, "too many too soon," distrust)
— Acknowledge concern, then provide presumptive recommendation: "Your child is due for MMR and varicella today."
— Avoid debate; share personal recommendation and document refusal with AAP refusal-to-vaccinate form
Step 3 management: For any suspected VPD, simultaneously (1) isolate the patient with appropriate precautions, (2) collect confirmatory specimens, (3) notify the local health department — do not wait for lab confirmation in measles, pertussis, meningococcal, or polio suspicion. Reporting is mandatory and time-sensitive.
— Kindergarten MMR coverage (CDC SchoolVaxView target ≥95%)
— Adolescent Tdap, HPV, MenACWY coverage (NIS-Teen)
— Adult influenza, Tdap, pneumococcal, shingles, COVID-19 coverage (BRFSS)
— Geographic clustering of exemptions ("hot spots") — even high state-level coverage can mask local pockets below HIT
— Rising case counts of a notifiable VPD
— Decreasing average age at infection (when coverage drops, susceptibles accumulate in older children — paradoxical age shift for rubella, mumps can cause more severe disease)
— Outbreaks in previously controlled regions
— Effective reproduction number Rₑ = R₀ × (1 − immune fraction); Rₑ > 1 means sustained transmission
— R₀ = transmission in fully susceptible population
— Rₑ (or Rₜ) = transmission accounting for current immunity; goal of public health intervention is Rₑ < 1
— Vaccine impact = (R₀ − Rₑ)/R₀
Key distinction: Vaccine efficacy (RCT-derived, ideal conditions) vs vaccine effectiveness (real-world, observational) vs vaccine impact (population disease reduction, includes herd effects). A vaccine with 90% efficacy and 70% uptake yields lower impact than one with 80% efficacy and 95% uptake — coverage often matters more than marginal efficacy for herd protection.
Board pearl: A "paradoxical" rise in adult rubella cases after partial childhood vaccination reflects shifted age-at-infection — and is why congenital rubella elimination requires sustained high coverage, not partial coverage.
— Suspected: fever ≥101°F + generalized maculopapular rash + cough/coryza/conjunctivitis
— Confirm: measles IgM (serum), measles RNA RT-PCR from nasopharyngeal/throat swab and urine
— IgG seroconversion (acute and convalescent) supports diagnosis
— Suspected: cough ≥2 weeks with paroxysms, whoop, or post-tussive emesis
— Confirm: nasopharyngeal PCR (best in first 0–3 weeks of cough), culture (specific but insensitive), serology for later disease in adolescents/adults
Step 3 management: When you suspect measles in clinic:
— Place patient in airborne isolation immediately (N95, negative-pressure room if available)
— Call public health before sending labs so they can coordinate specimen handling
— Identify all contacts in the waiting room (vaccine status, immunocompromise, pregnancy, age <12 mo) for post-exposure prophylaxis triage
CCS pearl: "Order: Measles IgM, measles PCR (NP swab + urine), notify public health, airborne isolation" — all on the same order screen, not sequentially.
— Measles, mumps, rubella, varicella: acceptable evidence = documented age-appropriate vaccination OR positive IgG serology OR lab-confirmed disease OR birth before 1957 (measles/mumps/rubella only; not varicella)
— Hepatitis B: anti-HBs ≥10 mIU/mL post-vaccination = immune; check 1–2 months after 3-dose series in HCWs and dialysis patients
— Tetanus, diphtheria, pertussis: serology not routinely used; rely on vaccination history
— Adults with uncertain records and contraindications to live vaccines (pregnancy, immunocompromise)
— Cost-effective for varicella in adults born outside the US
— Most healthy adults with uncertain MMR records — give MMR; no harm in revaccination
— Tdap: give every pregnancy at 27–36 weeks regardless of prior dosing
— Whole-genome sequencing of outbreak strains identifies transmission chains, importation source, and vaccine-derived strains
— Crucial for declaring elimination status (e.g., US measles elimination 2000 — threatened by post-2014 outbreaks)
— Test-negative case-control design (standard for influenza VE estimation)
— Cohort studies for varicella, HPV
— Post-licensure surveillance via VAERS (passive, hypothesis-generating), VSD (Vaccine Safety Datalink, active), CISA
Board pearl: A pregnant patient found to be rubella non-immune on prenatal labs should not receive MMR during pregnancy (live vaccine, theoretical fetal risk). Vaccinate postpartum before discharge — and counsel to avoid pregnancy for 28 days after MMR. This is a classic Step 3 transition-of-care item.
Key distinction: Birth before 1957 confers presumptive measles/mumps/rubella immunity from natural infection — but does not apply to varicella (varicella circulated freely until 1995 vaccine; older adults often had it, but documentation or serology is still preferred for HCWs).
— HIT = 1 − 1/R₀ assumes homogeneous mixing and lifelong sterilizing immunity — both often violated
— Real HIT is higher when: vaccine doesn't fully block transmission, immunity wanes, mixing is heterogeneous (assortative within communities)
— Real HIT is lower when: prior infection contributes immunity, behavioral changes reduce contact
— Tier 1 (coverage 90–95%, isolated exemption clusters): targeted outreach, school-entry enforcement, provider education
— Tier 2 (coverage 80–90% or growing pockets): remove non-medical exemptions (CA SB277 model), mandate catch-up, school exclusion during outbreaks
— Tier 3 (active outbreak): ring vaccination, post-exposure prophylaxis, isolation/quarantine, emergency exemption suspension
— Measles: MMR within 72 hours of exposure for immunocompetent ≥6 months; IG (IVIG or IMIG) within 6 days for infants <6 mo, pregnant non-immune, severely immunocompromised
— Varicella: varicella vaccine within 3–5 days for immunocompetent; VariZIG within 10 days for immunocompromised, pregnant non-immune, neonates of mothers with peripartum varicella
— Hepatitis B: HBIG + vaccine for non-immune exposures
— Hepatitis A: vaccine ≤2 weeks post-exposure (age 1–40); IG for <1 yo, >40, or immunocompromised
— Pertussis: azithromycin for close contacts regardless of vaccination status, especially household with infant
— Meningococcal: ciprofloxacin or ceftriaxone for close contacts; vaccination if outbreak strain matches available vaccine
Step 3 management: A 4-month-old exposed to measles in a pediatric waiting room → administer IMIG 0.5 mL/kg within 6 days (too young for MMR), then schedule MMR at 12 months. Quarantine the index case until 4 days after rash onset.
Board pearl: PEP timing windows are favorite distractors — measles MMR ≤72h, measles IG ≤6d, varicella vaccine ≤5d, VariZIG ≤10d, hep A vaccine ≤14d.
— MMR, varicella, MMRV, LAIV (nasal flu), rotavirus, yellow fever, oral typhoid, oral polio (not used in US), smallpox, BCG
— IIV (inactivated flu), Tdap, Td, IPV, HepA, HepB, HPV, MenACWY, MenB, PCV15/20/21, PPSV23, RSV (older adults, pregnancy, infants nirsevimab mAb), COVID-19, Hib, shingles (RZV, recombinant)
— Tdap every pregnancy 27–36 weeks (maternal antibody transfer protects infant from pertussis)
— Influenza any trimester during season
— COVID-19 per current recommendations
— RSV (RSVPreF/Abrysvo) at 32–36 weeks during Sept–Jan to protect newborn
— Td/Tdap every 10 years; one dose should be Tdap
— HPV through age 26 (shared decision 27–45)
— Zoster RZV 2 doses at age ≥50 (≥19 if immunocompromised)
— Pneumococcal: PCV20 or PCV21 alone, or PCV15 + PPSV23, for all ≥50 (recently lowered from 65) and high-risk younger adults
Key distinction: Egg allergy is no longer a contraindication to influenza vaccine of any type — any flu vaccine can be given; severe allergy may warrant medical setting observation but not avoidance. Anaphylaxis to a prior dose of the same vaccine remains an absolute contraindication.
Board pearl: MMR and varicella, if not given simultaneously, must be separated by ≥28 days — give same day or wait a month.
— Medical (all states) — true contraindications, documented by physician
— Religious (most states)
— Philosophical/personal belief (~15 states, declining)
— States that have eliminated non-medical exemptions: CA, MS, WV, NY, ME, CT — generally following major outbreaks (e.g., 2014–15 Disneyland measles → CA SB277)
— Created Vaccine Injury Compensation Program (VICP) — no-fault federal program
— Funded by $0.75 excise tax per vaccine antigen dose
— Plaintiffs must file in "vaccine court" (US Court of Federal Claims) before suing manufacturer
— Vaccine Injury Table lists presumed injuries (e.g., anaphylaxis within 4h, brachial neuritis after tetanus-containing within 2–28d)
— Burden of proof lower than tort; encourages reporting and protects vaccine supply
— VAERS — passive, anyone can report, hypothesis-generating, prone to bias
— VSD (Vaccine Safety Datalink) — active, integrates EHRs from ~12 million enrollees
— CISA — clinical consultation for complex adverse events
— BEST — FDA Sentinel-based active surveillance
Step 3 management: A patient asks whether to file a VAERS report after fever and arm soreness post-vaccination. Reassure that these are expected reactogenicity; VAERS is for unexpected, serious, or table-listed events. However, reporting is encouraged for any clinically significant event and is mandatory for healthcare providers for table injuries and EUA vaccines.
Board pearl: VICP covers vaccines on the childhood schedule; influenza vaccine for adults is also covered. COVID-19 vaccines fall under the separate Countermeasures Injury Compensation Program (CICP) — narrower, more restrictive.
— High-dose or adjuvanted influenza vaccines (Fluzone HD, Fluad, Flublok) preferred ≥65
— RZV shingles 2 doses (>90% efficacy, sustained)
— PCV20 or PCV21, or PCV15 + PPSV23 ≥1 year later
— RSV vaccine (single dose) for ≥75 and ≥60 with risk factors (shared decision)
— Tdap once, then Td or Tdap every 10 years
— COVID-19 boosters per current ACIP guidance
— Disproportionate severe outcomes (influenza, COVID-19, RSV, pneumococcus)
— Often live in congregate settings (SNFs, ALFs) where outbreaks spread rapidly
— Lower vaccine effectiveness means herd protection from younger vaccinated cohorts is critical
— CMS requires LTC facilities to offer influenza and pneumococcal vaccines and document refusals
— Reduced response to hepatitis B vaccine — give higher dose (40 mcg) 3-dose Engerix-B or 2-dose Heplisav-B; check anti-HBs post-series and annually
— Annual influenza, pneumococcal series, COVID-19, RSV per indication
— Live vaccines generally safe pre-transplant; contraindicated post-transplant
— Hepatitis A and B vaccination (if not immune) — universal recommendation
— Pneumococcal series, influenza, RSV
— Avoid live vaccines in decompensated cirrhosis
Step 3 management: A 68-year-old presents for Medicare wellness visit. Order checklist: influenza (high-dose), PCV20 if naïve, RZV ×2, RSV (shared decision), Tdap if not within 10 years, COVID-19 booster per schedule. Document each and update registry.
Key distinction: Zostavax (live, discontinued 2020) vs Shingrix/RZV (recombinant, current): RZV is preferred for all ≥50, and unlike Zostavax can be given to immunocompromised ≥19.
— Tdap every pregnancy at 27–36 weeks (optimizes transplacental pertussis antibodies)
— Influenza inactivated any trimester during season
— RSV (Abrysvo) at 32–36 weeks gestation Sept–Jan (alternative: infant nirsevimab)
— COVID-19 per current guidance
— Hepatitis B if not immune and at risk
— Birth: HepB
— 2/4/6 mo: DTaP, IPV, Hib, PCV, RV, HepB (some at 6m)
— 12–15 mo: MMR #1, varicella #1, Hib booster, PCV booster, HepA #1
— 4–6 yr: DTaP, IPV, MMR #2, varicella #2 boosters
— 11–12 yr: Tdap, HPV (2-dose if <15, 3-dose if ≥15), MenACWY #1
— 16 yr: MenACWY booster, MenB (shared decision 16–23)
— Avoid live vaccines (MMR, varicella, LAIV, yellow fever, rotavirus has nuances)
— Inactivated vaccines safe but less effective — may need additional doses (e.g., 3-dose primary COVID-19 series)
— Household contacts should be fully vaccinated including MMR and varicella to protect the patient (cocoon strategy)
— Avoid LAIV in household contacts of severely immunocompromised
— Rotavirus vaccine: live oral; OK in household contacts but practice hand hygiene during diaper changes
Board pearl: HIV with CD4 ≥200 (or ≥15% in children) for ≥6 months → MMR and varicella are recommended, not contraindicated. CD4 <200 → defer until immune reconstitution.
— Local: sore arm, redness, swelling
— Systemic: low-grade fever, myalgia, fatigue, headache — peak 24–48h
— Manage with acetaminophen/NSAIDs after (not prophylactically — may blunt antibody response in infants per some studies)
— Anaphylaxis: ~1 per million doses; onset minutes; treat with IM epinephrine 0.3–0.5 mg, observe; contraindication to repeat dose of same vaccine
— Febrile seizures: MMR/MMRV at 12–23 months — MMRV doubles risk vs separate MMR + varicella; ACIP recommends separate first dose, MMRV acceptable for second dose ≥4 yr
— Intussusception: rotavirus vaccines — small absolute increase (~1–5 per 100,000); restrict first dose to before 15 weeks, complete by 8 months
— Guillain-Barré syndrome: historical risk with 1976 swine flu vaccine ~1 per 100,000; current influenza vaccines minimal/no increased risk
— Myocarditis: mRNA COVID-19 vaccines in young males age 12–29, peak after dose 2, usually self-limited; risk lower than myocarditis from COVID-19 infection itself
— Thrombosis with thrombocytopenia syndrome (TTS): adenoviral COVID-19 vaccines (J&J withdrawn in US); manage like HIT — avoid heparin, use argatroban/fondaparinux
— Brachial neuritis: rare after tetanus-containing vaccines, on Vaccine Injury Table
— Measles: pneumonia (most common cause of death), acute encephalitis (1/1000), SSPE (1/10,000–100,000, years later, fatal)
— Pertussis: apnea and death in infants <2 months
— Rubella in pregnancy: congenital rubella syndrome (cataracts, sensorineural deafness, PDA, "blueberry muffin" rash)
— Varicella: bacterial superinfection, pneumonia (adults), encephalitis; zoster later in life
— HPV: cervical, anal, oropharyngeal cancers
— HepB: chronic hepatitis, cirrhosis, hepatocellular carcinoma
Key distinction: Anaphylaxis to a vaccine component (e.g., gelatin in MMR, neomycin) is a true contraindication; non-anaphylactic egg allergy is no longer a contraindication for any influenza vaccine. Pregnancy is a contraindication for live vaccines only.
Board pearl: Risk-benefit framing for question stems: severe measles complications (1/1000 encephalitis) vastly exceed serious MMR adverse events (~1/million anaphylaxis). Autism: no causal link — Wakefield 1998 paper retracted, multiple large studies refute.
— Measles, polio, diphtheria, smallpox, viral hemorrhagic fever, novel influenza, SARS/MERS — even one suspected case
— Healthcare-associated pertussis, varicella, or hepatitis B exposures
— Local health department: case investigation, contact tracing, PEP, school/workplace exclusion orders
— State health department: laboratory support, multi-jurisdictional coordination, exemption policy enforcement
— CDC: EpiAid deployment, genotyping, technical guidance, MMWR reporting
— WHO: international notification under IHR (2005) for events of international concern
— Isolation of cases (sick individuals) — measles airborne until 4 days after rash, varicella until lesions crust, pertussis until 5 days of effective antibiotic
— Quarantine of exposed susceptible contacts — measles 21 days from last exposure for non-immune
— School and daycare exclusion of unvaccinated children during outbreaks
— Healthcare worker furlough if non-immune and exposed
— Infection prevention: cohort patients, enhanced PPE, exposure logs
— Employee health: verify HCW immunity (measles, mumps, rubella, varicella, HepB, pertussis, influenza, COVID-19)
— OSHA Bloodborne Pathogens Standard mandates HepB vaccine offered free to at-risk workers
Step 3 management: Suspected measles case in your outpatient clinic →
1. Mask patient, place in negative-pressure room, vacate room for 2h after departure
2. Call public health (do not wait for confirmation)
3. Send measles IgM + PCR (NP and urine)
4. Identify exposed contacts (waiting room log, staff)
5. Triage contacts: vaccinated and immunocompetent → monitor; unvaccinated immunocompetent ≥6 mo → MMR within 72h; infants <6 mo, pregnant non-immune, immunocompromised → IG within 6 days
CCS pearl: Public health notification belongs on the initial order screen, not later — it changes the trajectory of the case and is required by law.
— Rubella: milder, postauricular and suboccipital lymphadenopathy, arthralgias in adults, no Koplik spots; major concern is congenital rubella in pregnancy
— Roseola (HHV-6): high fever 3–5 days then defervescence with rash; ages 6–24 months; not vaccine-preventable
— Erythema infectiosum (parvovirus B19): "slapped cheek," lacy reticular rash, no fever at rash stage; aplastic crisis in sickle cell, hydrops fetalis in pregnancy
— Scarlet fever (GAS): sandpaper rash, strawberry tongue, pharyngitis, Pastia lines; antibiotic-treatable
— Kawasaki disease: ≥5 days fever + 4/5 (conjunctivitis, mucosal changes, extremity changes, rash, cervical lymphadenopathy); coronary aneurysm risk
— Drug eruption, EBV with amoxicillin rash, secondary syphilis
— Varicella: crops in different stages, generalized, pruritic; vaccine-preventable
— HSV: localized cluster, recurrent
— Zoster: dermatomal, unilateral; preventable in older adults with RZV
— Hand-foot-mouth (coxsackie A): acral + oral lesions; not vaccine-preventable in US
— Disseminated zoster in immunocompromised — airborne precautions like varicella
— Mycoplasma pneumoniae: subacute cough, bullous myringitis, cold agglutinins
— Postviral cough, asthma, GERD, ACE-inhibitor cough
— RSV in infants: wheezing, apnea; preventable with maternal vaccine or infant nirsevimab
— Tuberculosis: chronic cough, weight loss, night sweats, hemoptysis; BCG used outside US
Key distinction: Koplik spots (white papules on buccal mucosa opposite molars, 1–2 days before rash) are pathognomonic for measles — distinguish from oral thrush, aphthous ulcers, Forchheimer spots (rubella, on soft palate).
Board pearl: A child with fever, conjunctivitis, coryza, cough, and rash spreading cephalocaudally from hairline + recent international travel + missing MMR = measles until proven otherwise — isolate immediately.
— Primary vaccine failure (no seroconversion, ~2–5%) vs secondary vaccine failure (waning immunity over years)
— Antigenic drift/shift (influenza) — vaccine match imperfect; not a failure of policy
— Vaccine-derived poliovirus (VDPV) — rare reversion from OPV (not used in US since 2000); reason US uses IPV exclusively
— Functional/anxiety-related symptoms at mass vaccination clinics — vasovagal syncope (observe 15 min post-dose, especially adolescents post-HPV/MenACWY)
— Coincidental events — temporal association ≠ causation; SIDS peaks at same age as 2/4/6-month vaccines but multiple large studies show no causal link
— ASIA syndrome, "vaccine injury" claims without table criteria — not supported by evidence
— Imported cases in well-vaccinated communities — single cases without secondary spread reflect successful herd immunity, not failure
— Vaccine-modified disease (e.g., breakthrough varicella with <50 lesions, no fever) — milder, still mildly contagious
— Confusing ACIP recommendations with FDA approval (FDA approves; ACIP recommends and CDC director adopts)
— Confusing VICP (childhood schedule + adult flu) vs CICP (COVID-19, anthrax, smallpox countermeasures)
— Confusing efficacy (RCT) vs effectiveness (real-world) vs impact (population)
— Confusing R₀ (basic) vs Rₑ/Rₜ (effective, with immunity/interventions)
— Parent refusing vaccines: not medical neglect per se unless imminent harm (e.g., refusing rabies PEP after bite)
— Adolescent seeking confidential vaccination (HPV, HepB) — varies by state minor consent laws
Key distinction: Outbreak in a highly vaccinated population does not mean the vaccine failed. Calculate proportion vaccinated among cases vs vaccine effectiveness — even with 95% effective vaccine and 95% coverage, in a large outbreak most cases may be vaccinated simply because most of the population is vaccinated (denominator effect).
Board pearl: "Most pertussis cases occurred in vaccinated children" — does NOT prove vaccine failure; reflects high coverage. Compute attack rates by vaccination status to assess effectiveness.
— Standing orders authorizing nurses to vaccinate without individual physician orders (Community Preventive Services Task Force, strong evidence)
— Reminder/recall systems via patient portal, text, mail — moves the needle 5–20 points
— Provider audit and feedback comparing coverage rates among peers
— Immunization Information Systems (IIS) / registries — every state has one; check before each visit
— Bundling with other preventive care (Medicare wellness visit, school physicals, prenatal care)
— Strong presumptive recommendation vs participatory language — "Charlie is due for three shots today" outperforms "What do you want to do about vaccines?"
— Vaccines for Children (VFC) program — free vaccines for Medicaid, uninsured, AI/AN, underinsured children at FQHCs
— Section 317 funds for adult vaccines in safety-net settings
— ACA coverage — ACIP-recommended vaccines covered without cost-sharing in non-grandfathered plans (preventive services)
— Medicare Part B covers influenza, pneumococcal, HepB (high-risk), COVID-19; Part D historically covered shingles, Tdap — Inflation Reduction Act moved all ACIP-recommended adult vaccines to $0 cost-sharing under Part D (2023)
— Medicaid covers ACIP-recommended adult vaccines without cost-sharing (IRA 2023)
— Address specific concerns; avoid information overload
— Use absolute risks not just relative
— Share that you vaccinated your own family
— Document refusals; revisit at every visit (recurring opportunity)
Step 3 management: A parent who refused MMR at 12 months returns at 18 months. Re-engage: acknowledge their thinking, ask what they have read, share your recommendation. If still refusing, document with AAP form, schedule next visit, and continue the relationship — do not dismiss families per AAP policy unless rare circumstances.
Board pearl: Removing cost barriers (IRA 2023) and adding standing orders are the highest-impact policy levers — favored Step 3 answer when stem asks "which intervention is most likely to increase coverage."
— Update IIS at every visit
— Schedule next vaccine before patient leaves (use age-based reminders)
— Annual influenza in fall (Sept–Oct ideal, before peak)
— Tdap booster q10 yr (Td acceptable but ACIP allows Tdap each time)
— Document anti-HBs in HCWs and dialysis patients
— NIS (National Immunization Survey): annual coverage estimates for children 19–35 months, adolescents, adults
— SchoolVaxView: kindergarten coverage and exemption rates by state
— BRFSS: adult vaccine coverage
— NHANES: serologic immunity (e.g., HepB anti-HBs prevalence)
— HEDIS Childhood Immunization Status (CIS) — Combo 10: DTaP, IPV, MMR, Hib, HepB, varicella, PCV, HepA, RV, influenza by age 2
— HEDIS Adolescent Immunization Status (IMA) — meningococcal, Tdap, HPV by age 13
— HEDIS Adult Immunization Status (AIS-E) — flu, Td/Tdap, zoster, pneumococcal
— CMS Star Ratings for Medicare Advantage and ACO performance
— Address vaccine hesitancy longitudinally (motivational interviewing across visits)
— Connect with community health workers and trusted community voices
— Tailor outreach for high-risk groups (pregnancy clinics, oncology, dialysis, LTC)
— Wastewater surveillance (polio, SARS-CoV-2)
— Sentinel ILI surveillance (ILINet, FluView)
— Genomic surveillance for variants
Step 3 management: A diabetic 55-year-old at routine follow-up — quick audit: flu (this season?), Tdap (within 10 yr?), PCV20 (eligible at 50+), HepB (recommended for diabetics 19–59, shared decision ≥60), zoster RZV (if ≥50), COVID-19 booster per schedule. Document and order via standing orders.
Key distinction: HEDIS measures drive payer quality bonuses; MIPS/MVP measures drive Medicare physician reimbursement — both reinforce vaccination at the system level, making clinic workflows (not patient willpower) the key intervention point.
— National Childhood Vaccine Injury Act mandates the most current Vaccine Information Statement (VIS) be provided to patient/parent before each dose, with date documented in chart
— Verbal review encouraged but written provision is legally required
— Document lot number, manufacturer, site, route, administrator name
— Notifiable VPDs (measles, pertussis, etc.) — clinician reporting is legally mandated in all states; failure can incur fines
— VAERS — mandatory for healthcare providers for table injuries, EUA vaccines, and any event that prompts vaccine refusal in the future
— Parents have authority to consent on behalf of minors but cannot refuse clearly lifesaving treatment (e.g., post-rabies bite vaccination)
— Routine vaccine refusal is not medical neglect absent imminent harm
— Document refusal with AAP "Refusal to Vaccinate" form
— Some states allow mature minor or specific-condition consent (HPV, HepB, STI) without parental involvement
— Constitutionally upheld (Jacobson v. Massachusetts, 1905; Zucht v. King, 1922)
— Religious accommodation under Title VII may apply to employer mandates — case-by-case
— Hospitalized patients — discharge is a high-yield moment to give influenza, pneumococcal, Tdap, COVID-19 (CDC and Joint Commission recommend)
— Postpartum unit — rubella non-immune mother gets MMR before discharge with documentation and counseling
— NICU graduates — vaccinate by chronologic (not corrected) age; do not delay
— Splenectomy patients — meningococcal, pneumococcal, Hib ≥14 days before elective splenectomy or ≥14 days after emergency splenectomy
— Oncology — vaccinate before chemotherapy when possible; live vaccines off-limits during and for 3–6 months after
— Tuskegee, Henrietta Lacks, and immigration enforcement history → legitimate mistrust requiring active rebuilding via community engagement
— Language-concordant materials, culturally tailored outreach
Step 3 management: Asplenic patient admitted for emergency splenectomy → schedule PCV20, MenACWY, MenB, Hib to begin 14 days post-op, and counsel on lifelong pneumococcal and meningococcal boosters and antibiotic prophylaxis (penicillin) in children <5 yr post-splenectomy. This is a classic discharge planning omission on boards.
Board pearl: Standing orders and EHR best-practice alerts reduce missed-vaccination errors — a patient safety / quality improvement answer when stems describe missed opportunities.
Key distinction: R₀ vs Rₑ: R₀ is intrinsic to pathogen and population; Rₑ reflects current immunity and interventions. Public health goal: drive Rₑ <1.
Board pearl: "The single most effective intervention to increase coverage" = removing barriers (cost, standing orders, reminder/recall). Education alone is rarely the answer.
A 6-month-old at a pediatric office is exposed to a child later confirmed to have measles. The infant has received no MMR. Best next step?
→ Immune globulin (IMIG 0.5 mL/kg) within 6 days; MMR at 12 months as scheduled. (Too young for MMR PEP <6 mo.)
R₀ for measles is 15. What proportion of the population must be immune to achieve herd immunity?
→ 1 − 1/15 = 93.3%.
Rubella IgG negative on prenatal labs. Best management?
→ Postpartum MMR before discharge; avoid pregnancy 28 days; do not give during pregnancy.
Nurse with no documented immunity exposed to varicella. Best next step?
→ Check varicella IgG; if negative and immunocompetent → varicella vaccine within 3–5 days; furlough days 8–21 post-exposure.
After eliminating non-medical vaccine exemptions, kindergarten MMR coverage rose from 87% to 96%. This intervention most directly addresses which determinant of herd immunity?
→ Increasing the immune fraction of the population above HIT.
In a measles outbreak, 70% of cases occurred in vaccinated individuals. Best interpretation?
→ Does not mean vaccine failure; calculate attack rates by vaccination status. If coverage is 95%, even 70% of cases being vaccinated is consistent with high effectiveness.
65-year-old admitted with CAP, never vaccinated against pneumococcus. Discharge orders?
→ PCV20 (or PCV21) before discharge; flu vaccine if in season; Tdap if not within 10 yr; document in registry.
Patient undergoing elective splenectomy. When to vaccinate?
→ ≥14 days before surgery with PCV20, MenACWY, MenB, Hib.
Parent refuses MMR citing autism concern. Best response?
→ Acknowledge concern, share evidence and your recommendation, document refusal, continue relationship, revisit at next visit.
Child has anaphylaxis after MMR. Next step (legal)?
→ Report to VAERS (mandatory for table event); family may file with VICP; do not give future MMR doses.
Board pearl: When asked for the "most cost-effective" or "highest-impact" population intervention, lean toward systems-level answers (standing orders, removing cost, IIS reminder/recall, mandates with limited exemptions) rather than individual education.
Herd immunity is achieved when the immune fraction of a population exceeds the threshold 1 − 1/R₀, interrupting sustained transmission and protecting those who cannot be vaccinated — and US vaccine policy (ACIP recommendations, school mandates with narrow exemptions, VFC/IRA cost elimination, VICP no-fault compensation, and active surveillance via VAERS/VSD) is the systems-level scaffolding that makes that threshold achievable in practice.
High-yield recap bullets:
Final board pearl: When in doubt, the right answer combines isolate + report + PEP + catch-up + document — the five-part anatomy of every herd-immunity stem on Step 3.